Forum Topic News
  • Conversation: AZ strengthens Daiichi Sankyo partnership with new ADC deal

    • July 27, 2020 8:05 PM BST
      • Post(s)

      AZ strengthens Daiichi Sankyo partnership with new ADC deal

      AstraZeneca (AZ) has invested up to $6bn in a new partnership with Japanese pharma company Daiichi Sankyo (Daiichi) for the development of a novel antibody drug conjugate (ADC).
      The focus of the deal is an experimental ADC – DS-1062 – which is currently in development for the treatment of a number of multiple tumours which express the cell-surface glycoprotein TROP2.
      According to AZ, TROP2 is over-expressed in the majority of non-small cell lung cancers (NSCLC) and breast cancers. Both cancer types are of particular interest for AZ as it plans to extend its oncology franchise beyond its approved therapies, which include PD-1 inhibitor Imfinzi (durvalumab), lymphoma treatment Calquence (acalabrutinib) and its recently approved, Daiichi-partnered HER2-targeting ADC, Enhertu (trastuzumab deruxtecan).
      Enhertu was the focus of a previous collaboration between AZ and Daiichi – in March 2019, AZ agreed a $6.9bn deal for access to the drug. Last December, the therapy was approved by the US Food and Drug Administration (FDA) for the treatment of metastatic HER2-positive breast cancer in patients who have been previously treated with two or more HER-2-based regimens.
      Read more:

Add Reputation

Do you want to add reputation for this member by this post?

or cancel